SYMPHONY PREDICTIONS

SYMPHONY PREDICTIONS

At Aria, we are constantly improving our prediction capabilities. This allows our scientists to select and advance lead candidates that have the best likelihood of success at Phase 1 and Phase 2 milestones. In fact, our combined likelihood of success in preclinical and Phase 2 milestones is over 50x higher than traditional research and development approaches.


In addition to our own pipeline, we’ve created clinical predictions for existing Phase 2 candidates. The list below represents candidates that our Symphony™ drug discovery platform predicts will achieve efficacy in their respective Phase 2 trials. Stay tuned for additional quarterly updates.

clinical trials ending in q4 2022

Published on August 31, 2022. 

DISEASE

DRUG

MECHANISM OF ACTION

NOVEL MECHANISM OF ACTION IN DISEASE

CLINICAL TRIAL

END DATE

CLINICAL TRIAL LINK

ADDITIONAL COMMENTS

Idiopathic Pulmonary Fibrosis (IPF)

BMS-986263

SERPINH1-

Yes

September 2022

clinicaltrials.gov

Nonalcoholic steatohepatitis (NASH)

Efinopegdutide

GCGR+ GLP1R+

No

October 20, 2022

clinicaltrials.gov

Ankylosing Spondylitis

Jaktinib 

JAK1- JAK2- JAK3-

No

December 22, 2022

clinicaltrials.gov

While we're predicting efficacy for Jaktinib, we do have questions about its tolerability given its pan-JAK MOA.

Epilepsy

DARIGABAT

GABRA1? GABRA2+ GABRA3+ GABRA5+ GABRB2? GABRB3? GABRG2? 

No

November 2022

clinicaltrials.gov

Atopic Dermatitis

CMK-389

IL18-

Yes

October 6, 2022

clinicaltrials.gov

Atopic Dermatitis

CENDAKIMAB

IL13-

No

November 13, 2022

clinicaltrials.gov

Atopic Dermatitis

Jakinib

JAK1- JAK2- JAK3-

No

December 2022

clinicaltrials.gov

While we're predicting efficacy for Jaktinib, we do have questions about its tolerability given its pan-JAK MOA.

SYMPHONY™

Aria’s drug discovery engine.

Drug discovery is complex. Our technology decodes complex biology in an unprecedented manner, combining the widest biomedical data landscapes available with proprietary, purpose-built artificial intelligence. Symphony™ is the only AI drug discovery platform that integrates and simultaneously analyzes unrelated heterogenous data in one process. We see the whole picture, increasing our chance of fully understanding the biology and detecting a signal others can’t see.